Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer (iCCA)

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement